Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting entities : Cellectis s.a. save search
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 4.83%
H: 0.0%
C: -2.48%
talen for meeting
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
Published: 2023-12-22 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
ORTX | $16.7 0.0% 370K
|
Health Technology
| Email alert
Add to watchlist
meeting results
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Published: 2023-11-17 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
meeting
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -5.98%
H: 4.24%
C: 1.06%
trials meeting results
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-10-31 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 179.38%
H: 10.33%
C: -2.58%
pre-clinical breast cancer immunotherapy meeting
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -1.25%
H: 2.22%
C: 0.0%
pre-clinical breast cancer immunotherapy meeting
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
Published: 2023-06-28 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -0.74%
H: 0.74%
C: -0.84%
meeting results
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Published: 2023-05-02 (Crawled : 20:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 4.11%
H: 1.84%
C: -2.11%
ameli-01 presentation cell meeting therapy
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-04-17 (Crawled : 07:00) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.0%
talen breast association cancer research preclinical meeting negative
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -3.54%
H: 2.09%
C: -4.19%
talen research meeting breast association presentation cancer negative
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Published: 2022-10-05 (Crawled : 23:00) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -3.73%
H: 7.32%
C: 2.59%
talen immunotherapy pre-clinical smart meeting
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
Published: 2022-05-23 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -2.71%
H: 1.67%
C: 0.84%
Cellectis Presents Preclinical Data from its First Allogeneic Dual CAR T-cell Product Candidate UCART20x22 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Published: 2022-04-08 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
ucart20 research preclinical t-cell cancer pre-clinical
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-11 (Crawled : 16:20) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
balli-01 ema leukemia preclinical t-cell pre-clinical
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
immunotherapy solid tumors therapy car-t cancer ucartmeso preclinical t-cell pre-clinical
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-10-12 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 6.78%
H: 1.23%
C: -1.54%
immunotherapy therapy cancer ucartmeso preclinical pre-clinical
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
Published: 2021-06-02 (Crawled : 07:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: -1.9%
H: 1.31%
C: -5.24%
results
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021
Published: 2021-04-26 (Crawled : 21:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -2.01%
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
Published: 2020-12-05 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
| Email alert
Add to watchlist
results phase 3 phase 1 phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.